When insulin isn't enough: targeting glucagon in type 1 diabetes
- PMID: 36192555
- DOI: 10.1038/s41591-022-02019-3
When insulin isn't enough: targeting glucagon in type 1 diabetes
Comment on
-
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.Nat Med. 2022 Oct;28(10):2092-2099. doi: 10.1038/s41591-022-02011-x. Epub 2022 Oct 3. Nat Med. 2022. PMID: 36192552 Free PMC article. Clinical Trial.
References
-
- Foster, N. C. et al. Diabetes Technol Ther. 21, 66–72 (2019). - DOI
-
- Pettus, J. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02011-x (2022). - DOI - PubMed
-
- Unger, R. H. & Orci, L. Proc. Natl Acad. Sci. USA 107, 16009–16012 (2010). - DOI
-
- Brown, R. J., Sinaii, N. & Rother, K. I. Diabetes Care 31, 1403–1404 (2008). - DOI
-
- Sherr, J. et al. Diabetes Care 37, 1741–1744 (2014). - DOI